Acellera Therapeutics and Psivant Therapeutics have announced a strategic research partnership aimed at developing computational drug discovery approaches with the help of AI and quantum simulations.
The partnership will combine Psivant’s Quaisar platform with Acellera’s AceForce technology.
Go deeper with GlobalData
Employing neural network potential, the AceForce technology aims for accurate delivery of protein-ligand potency predictions at “exceptional” speed.
Psivant’s Quaisar combines computational physics and AI with expertise in disease chemistry, biology, biophysics and translational informatics.
The partnership seeks to address challenges in small molecule screening and design of drugs by integrating AI, quantum chemistry simulations and machine learning with methods based on physics along with lab-based testing.
Acellera Therapeutics CEO Gianni De Fabritiis stated: “We are excited to collaborate with Psivant and harness the power of QuantimBind and PlayMolecule to pioneer new computational approaches to designing therapeutics.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAcellera’s QuantumBind, an integrated platform for small molecule discovery and potency optimisation, will work in tandem with the virtual environment of PlayMolecule for drug discovery that integrates simulations, AI and data.
Jointly funded by the European Regional Development Fund, the partnership seeks to combine AI-driven insights with experimental workflows, enhancing both companies’ positions in the discovery of small-molecule therapeutics.
Psivant Therapeutics chief innovation officer Woody Sherman stated: “By bringing together state-of-the-art computational methods with our drug discovery expertise and in-house lab, we aim to deliver effective therapeutics for some of the most challenging disease targets.
“We look forward to combining Acellera’s cutting-edge AI and Quantum technologies with our validated QUAISAR platform — bringing innovative medicines to patients faster.”
Acellera Therapeutics focuses on drug discovery by merging AI-driven innovation with computational scaleability, aiming to expedite the development of future medicines.
